

AMENDMENT

Please insert the following claim of priority:

“This application is a continuation application of U.S. Serial No 10/207,399, filed on July 29, 2002 which is a continuation-in-part application of U.S. Serial No. 09/226,580 filed January 7, 1999 which is a continuation-in-part application of U.S. Serial No. 09/833,842 filed April 10, 1997, which is a continuation –in-part application of U.S. Serial No.. 08/693,882 filed August 5, 1996, now U.S. Patent No. 5,767,160 dated August 6, 1996, which is a continuation-in-part application of U.S. Serial No. 08/321,051 filed October 5, 1994, now U.S. Patent No. 5,543,430 dated June 16, 1998.”

REMARKS

The amendments made herein serve to further describe the various embodiments as set forth in the original drawings, specification and claims. No new matter is added by the amendments made herein. Support may be found at page 16-19, wherein the biological effects of citrulline and various Hmg-CoA reductase inhibitors are described.

Specifically, support for the Hmg-CoA reductase inhibitors may be found in the second paragraph on page 20 of the 10/207,399 Application. This paragraph lists various suitable Hmg-CoA reductase inhibitors or incorporates by reference several patents which describe suitable Hmg-CoA reductase inhibitors. It states in its entirety that:

L-arginine may be used in conjunction with virtually any of the family of those substances known as Hmg-CoA reductase inhibitors. These are taught for example in U.S. Pat. Nos. 4857522, 5,190,970, and 5,461,039, all of which are hereby incorporated by reference for this teaching. Those particular Hmg-CoA reductase inhibitors most preferred for use in conjunction with the present formulation as selected from the group consisting of: atorvastatin, cerivastatin, simvastatin, lovastatin, pravastatin, compactin, fluvastatin, and dalvastatin. U.S. Pat. No. 5,316,765 cites a number of these Hmg-CoA reductase inhibitors and is hereby incorporated by reference in its entirety. In particularly preferred embodiments

of the present invention, the Hmg-CoA reductase inhibitor utilized is pravastatin or atorvastatin. In an even more particularly preferred embodiments, the administration of the present invention includes the Hmg-CoA reductase inhibitor pravastatin.

Therefore, the inhibitors atorvastatin, cerivastatin, pravastatin, simvastatin, lovastatin, compactin, fluvastatin, and dalvastatin are specifically supported by page 20 of the '399 Application . The inhibitors mevastatin and velostatin are described in U.S. Patent No. 5,190,970. See column 4, line 63-68. The inhibitor fluindostatin is described in U.S. Patent No. 5,461,039. See column 8, line 25. The inhibitors compactin, fluvastatin, dalvastatin, and simvastatin are described in U.S. Patent No. 5,316,765. See column 3, lines 3-16.


The present application contains support for the recitation of citrulline in the presently filed claims. See page 4 of the 10/207,399 Application, which describes the "L-arginine" term to include citrulline.

In addition to the specifically listed support of the use of citrulline in the presently claimed compositions and methods, there is support of citrulline through reference. There are several references which are incorporated by reference into the current application as filed. These references include: U.S. Serial No. 10/207,399 entitled "A Therapeutic Mixture Useful in Inhibiting Lesion Formation After Vascular Injury", which claims priority to U.S. Patent No. 6,425,881; U.S. Patent No., 6,239,172; U.S. Patent No. 5,968,983; U.S. Patent No. 5,767,160; and U.S. Patent No. 5,543,430.

U.S. Patent No. 5,767,160 includes claims directed to the biological equivalents of "L-arginine". Specifically listed as an equivalent is citrulline. See claims 3 and 10, and column 4, lines 37 - 43.

In the event that an additional fee is required for this amendment, the
Commissioner is hereby authorized to charge such additional fee to Deposit Account no. 50-
0436.

Respectfully Submitted,

A handwritten signature in black ink, appearing to read "Raymond A. Miller", is written over a horizontal line.

Raymond A. Miller
Registration No. 42,891

Pepper Hamilton, LLP
500 Grant Street
Pittsburgh, PA 15219-2502
(412) 454-5813

Dated: January 23, 2004